Hepatocellular Carcinoma
Conditions
Keywords
hepatocellular carcinoma
Brief summary
Clinical trials can sometimes favor certain demographic groups. Additionally, there is limited research that delves into the factors that influence participation in clinical study, both positive and negative. The goal is to identify the obstacles and challenges that prevent participation in hepatocellular carcinoma clinical research, as well as the reasons for withdrawal or discontinuation. Insights gained from this study will ultimately benefit those with hepatocellular carcinoma who may be invited to participate in clinical research in the years to come.
Interventions
None listed
Sponsors
Power Life Sciences Inc.
Study design
Observational model
CASE_CROSSOVER
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Diagnosed with hepatocellular carcinoma * Willing to comply with all study related procedures and assessments * Capable of giving signed informed consent, which includes compliance with requirements and restrictions listed in the informed consent form (ICF) and in the protocol
Exclusion criteria
* No documented diagnosis of hepatocellular carcinoma * Any serious and/or unstable pre-existing medical disorders * Pregnant or lactating woman
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Rate of patients who decide to enroll in a hepatocellular carcinoma clinical study. | 3 months |
| Number of hepatocellular carcinoma study participants who remain in clinical trial until completion. | 12 months |
Contacts
Primary ContactMichael B Gill
Outcome results
None listed